CoQ

Coenzyme Q10 (Ubidecarenone) 30 mg Capsule is indicated for Coenzyme Q10 deficiency and mitochondrial disorders. It is also used as adjunctive therapy in congestive heart failure, myocardial infarction, and high blood pressure (hypertension) in combination with other medications. Additional uses include prevention of migraine headache, supportive management in Parkinson's disease, improvement of immune function, male infertility, and muscular dystrophy.

Dosage should be individualised based on the clinical indication. The following doses have been used in clinical studies:

• CoQ10 deficiency (primary): 5–50 mg/kg/day
• Hypertension (adjunctive): 120–200 mg daily in divided doses
• Migraine prophylaxis: 100–400 mg daily
• Parkinson's disease (adjunctive): 300–2400 mg daily
• Statin-related muscle pain: 50 mg twice daily
• General supplementation: typically 100–300 mg daily

For doses exceeding 100 mg per day, it is advisable to divide the total daily dose into two or three administrations to minimise gastrointestinal side effects.

Coenzyme Q10 capsules should be taken orally. Absorption is significantly improved when taken with a meal containing fat. For doses exceeding 100 mg per day, the total daily dose should be divided into two or three separate administrations.

Coenzyme Q10 (Ubidecarenone) is a fat-soluble, vitamin-like molecule naturally present in every cellular membrane and endogenously synthesised in the body. It exists in two interconvertible forms: the oxidised form (ubiquinone) and the reduced form (ubiquinol), which accounts for approximately 95% of circulating CoQ10.

Mechanism of Action

CoQ10 functions primarily as an electron carrier in the mitochondrial respiratory chain, facilitating ATP synthesis through oxidative phosphorylation. In addition to its role in energy production, it acts as a potent antioxidant by enhancing superoxide dismutase activity and reducing lipid peroxidation. It also improves blood flow and helps preserve nitric oxide in blood vessels.

Pharmacokinetics

After oral administration, CoQ10 is absorbed through the lymphatic system and incorporated into chylomicrons, then redistributed via VLDL, LDL, and HDL lipoproteins. Peak plasma concentrations are typically reached 5.80 to 8.10 hours after ingestion, depending on formulation. Absorption is enhanced when taken with a fatty meal and with solubilised formulations. Highest tissue concentrations are found in the heart, liver, kidneys, and muscles. CoQ10 is reduced to ubiquinol in the small intestine; metabolites are phosphorylated and transported through plasma. Elimination is primarily biliary and faecal, with a small fraction eliminated in the urine.

Coenzyme Q10 is generally well tolerated. Side effects are infrequent and usually mild.

Gastrointestinal (less than 1% of patients): Nausea, vomiting, diarrhoea, upset stomach, stomach pain, heartburn, decreased appetite, and epigastric discomfort. These effects are reversible.

Dose-related effects:

• Doses ≥100 mg/day: mild insomnia in some patients.
• Doses ≥300 mg/day: transient elevation of liver enzymes (no hepatotoxicity reported at these levels).

Other reported effects: Dizziness, headache, fatigue, irritability, photophobia, skin rash, and lowered blood pressure.

• Known hypersensitivity to Coenzyme Q10 (Ubidecarenone) or any excipient in the formulation.
• Biliary obstruction, as CoQ10 is primarily eliminated via bile.
• Concurrent use with chemotherapy, owing to insufficient safety data.

• Patients with diabetes should be monitored carefully, as CoQ10 may lower fasting blood glucose levels, increasing the risk of hypoglycaemia when used alongside antidiabetic agents.
• Patients taking anticoagulants (e.g., warfarin) require close monitoring of coagulation parameters due to a potential reduction in anticoagulant efficacy.
• Patients taking antihypertensive medications should be monitored for excessive blood pressure reduction.
• Patients with renal impairment: limited evidence is available; use should be restricted to cases of primary CoQ10 deficiency in this population.
• Patients with biliary obstruction should avoid CoQ10, as biliary excretion is the primary elimination route.
• For primary CoQ10 deficiency, periodic monitoring is recommended, including urinalysis (for proteinuria), renal function tests, neurological evaluation, ophthalmological assessment, and audiometry.
• To minimise gastrointestinal side effects, total daily doses exceeding 100 mg should be divided into two or three administrations per day.

Elderly patients

No specific dose adjustments have been established for older adults. CoQ10 is generally considered relatively non-toxic in this population.

Pediatric patients

No age-specific dosing recommendations are available for general use. For primary CoQ10 deficiency, weight-based dosing of 5–50 mg/kg/day has been used. There are limited data on relative toxicity in infants.

Renal impairment

Limited evidence is available. Use should generally be restricted to documented primary CoQ10 deficiency in patients with renal impairment.

Hepatic impairment

No specific guidance is available. Use with caution, given that CoQ10 is primarily eliminated via biliary and faecal routes.

Pregnancy

Manufacturers do not recommend the use of Coenzyme Q10 during pregnancy due to insufficient safety data. It is not known whether CoQ10 supplementation could affect pregnancy or harm a foetus. Use during pregnancy should only be considered under medical supervision.

Lactation

Coenzyme Q10 is a normal component of human breast milk and occurs naturally as part of the diet and through endogenous synthesis. However, no data exist on the safety and efficacy of CoQ10 supplementation in nursing mothers or infants, and milk levels following exogenous administration have not been measured in humans. Manufacturers do not recommend use during breastfeeding. Consult a physician before use.

Coenzyme Q10 has been reported to be well tolerated at doses up to 1200 mg per day. No toxic blood level has been established, and toxicity is unlikely at standard supplementation doses. In the event of suspected overdose, general supportive measures should be applied. No specific antidote is known.

Warfarin and other anticoagulants: Coenzyme Q10 is structurally similar to vitamin K and may reduce the anticoagulant effect of warfarin, potentially increasing the risk of blood clots. This interaction is considered reversible. Patients on warfarin therapy should be monitored closely.

Antihypertensive agents: CoQ10 may produce an additive blood pressure-lowering effect when used concurrently with antihypertensive medications, potentially causing excessive reduction in blood pressure.

Insulin and antidiabetic agents: CoQ10 may lower fasting blood glucose in some patients, and pharmacodynamic synergism with insulin or other antidiabetic agents is possible, increasing the risk of hypoglycaemia.

Statins: Statins (e.g., atorvastatin) may decrease endogenous CoQ10 levels through an unspecified interaction mechanism.

Chemotherapy: Insufficient data are available on the interaction between CoQ10 and chemotherapy agents; caution is advised.

Store at room temperature between 20°C and 25°C (68°F and 77°F). Keep out of reach of children.

What is the price of CoQ 30 mg in Bangladesh (BD)?

CoQ 30 mg price in Bangladesh is ৳8.02 per capsule. Prices may vary by pharmacy and are updated regularly on this page.

What is CoQ used for?

Coenzyme Q10 (Ubidecarenone) 30 mg Capsule is indicated for Coenzyme Q10 deficiency and mitochondrial disorders. It is also used as adjunctive therapy in congestive heart failure, myocardial infarction, and high blood…

Is CoQ an antibiotic?

No, CoQ is not an antibiotic.